Iswanto Sucandy, MD, Gintaras Antanavicius, MD, FACS, Fernando Bonanni, MD, FACS
Abington Memorial Hospital, Department of Surgery
Introduction: Laparoscopic vertical sleeve gastrectomy (LSG) was initially performed as the first stage of biliopancreatic diversion with duodenal switch and is now considered a definitive procedure because of its promising early and midterm results. As a relatively new operation however, the effects of LSG on obesity-related comorbidities have not been adequately investigated. This study was designed to evaluate resolution or improvement of the common obesity-related comorbidities (diabetes mellitus, hypertension, and hyperlipidemia) after LSG.
Methods: A prospectively maintained database of all patients who underwent LSG between 2008 and 2011 was reviewed.
Results: A total of 131 consecutive patients (female : male = 98:33) were included with mean age of 49.4 years (range: 19-79), BMI of 48.9 kg/m2 (range: 34-84). The average number of preoperative comorbidities was 3.9 (range: 0-12). Mean operative time was 106 minutes (range: 48-212) without intraoperative complications. Among the common obesity-related comorbidities, hypertension was found in 55% of patients, followed by diabetes mellitus (33%), and hyperlipidemia (36%). At 1 year after LSG, the highest resolution was seen with diabetes mellitus (72%), followed by hypertension (55.5%), and hyperlipidemia (50%). All diabetic patients experienced improved control of their hyperglycemia (either complete resolution or less severe disease) at 18 months postoperatively. Significant improvements in hypertension and hyperlipidemia were seen in 36.1 % and 19.6 % of patients, respectively. Percentages of excess body weight loss (EBWL) at 1,3,6,9,12, and 18 months postoperatively were 19.3%, 31%, 44.5%, 50%, 57.3%, and 65.2%, respectively. No mortality occurred in this study.
Conclusions: Laparoscopic sleeve gastrectomy is an effective weight loss procedure with satisfactory resolution or improvement of diabetes mellitus, hypertension, and hyperlipidemia.
Session: Poster Presentation
Program Number: P404
